

**European LeukemiaNet Consortium
WP 9 - CMPD**

Minute of the Heidelberg Meeting, 1 February 2005

The following investigators attended the Meeting: Guido Finazzi (Bergamo), Tiziano Barbui (Bergamo), Gunnar Birgegard (Uppsala), Annette Schmitt-Graff (Freiburg), Hans Hasselbalch (Denmark), Martin Griesshammer (Ulm), Andreas Reiter (Heidelberg), Jean-Jacques Kiladjian (Paris), Eva Lengfelder (Heidelberg), S. Zweegman (NL) and some other unidentified attendants.

Past: deliverables months 1-12

Tiziano Barbui introduced the meeting and Guido Finazzi reviewed the list of the deliverables already delivered in the first year of activity of the group. Major points of discussion were:

- a) how to implement the use of our ELN-WP9 web-site: several potential uses of the web-site have been outlined (protocols update, on-line registries, information for the patients and others) but this requires time and work. Final agreement was that Guido Finazzi as coordinator will send Andreas Reiter, as our web-master, a list of changes necessary for updating at least our presentation page and for uploading our documents distinguishing those for public domain and those for private, i.e. WP only, use;
- b) to implement a Registry of Hereditary MPDs asking Dr. Radek Skoda to join the WP and to coordinate a group interested in this issue; Prof. Barbui will ask dr. Skoda for this;
- c) to complete the deliverables particularly with the proposal of diagnostic, prognostic and staging definitions to be used in the future clinical trials of the WP (see below). This is up to dr. Gianni Barosi.

Future: deliverables months 13-30

The deliverable list for the next period was reviewed and discussed. Major points were:

- a) protocol and funding for the phase II study of Imatinib in PV; after a talk of Prof. Barbui with dr. Fincato, European Oncology Director of Novartis, the following agreement was decided: a contract will be signed by Novartis and Barbui, Hasselbalch and Lengfelder for funding the study; in the meantime, drs. Hasselbalch and Lengfelder will draft the study protocol; Novartis will be the sponsor of the study;
- b) a general strategy for approval and dissemination of this and other planned WP9 clinical study was decided: the protocol draft together with a financial plan should be circulated and approved by the steering committee members; in turn, each member will present the protocol to their respective national MPD study group(s) asking for their participation in the study;
- c) implementation of Registries are up to the respective proponents; dr. Birgegard presented a protocol for a non-interventional, prospective, registration study of patients treated with Anagrelide for long-term safety and efficacy evaluation. The study is supported by Shire and will follow the general rules for approval and dissemination stated in the point b) above.

The next WP9 meeting is scheduled during the forthcoming EHA Congress in Stockholm, possibly Friday June 3, 2005 hour 20.30 after the EWG-MPD session. Dr. Birgegard agreed to be our local organizer for a dinner-meeting, if possible. Gunnar Birgegard and myself will confirm this appointment to all of you ASAP.

Best wishes to all.

Guido Finazzi

Bergamo 5/2/05